Replies to post #25497 on Amarin Corp Plc (AMRN)

[ziploc_1]

BiChica,I agree:
Amarin has numerous very strong patents for Vascepa. Also, Amarin has a large amount of exclusive supply for Vascepa. The patents are simple and straight forward as compared with patents on cell phones or autos. They should be relatively easy to defend against infringing generic competition until 2030. In fact I do expect infringing generic competitors to appear after REDUCE-IT shows excellent results in their interim release. These generic infringers may serve as advertisements for Vascepa while Amarin defends its patents.

[no_mo_Butterfinger]

As opposed to others, I do NOT WELCOME generic filings & law suits & lawyer fees & patent challenges & further erosion in stock price. Now is certainly NOT a good time for all this.

[sts66]

Be careful what you wish for - defending multiple ANDA challenges is enormously expensive to a tiny company like AMRN.